Proud Pangolin
Member
Has anyone tried it? Looks very promsing on paper. The fatloss of t3 without the catabolic and heart effect.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.

I think doses go from 25mcg to 100mcg a day.Seems really interesting. Originally intended to be add-on therapy with statins for lipids + cholesterol, but also has fat-burning and insulin sensitivity effects.
Highlights:
- “Sobetirome binds selectively to the main hepatic form of thyroid hormone receptor, TRβ1, compared to TRα1, which is principally responsible for thyrotoxic effects on heart, muscle and bone. Sobetirome also preferentially accumulates in liver, enabling stimulation of hepatic pathways that lower cholesterol without harmful side effects.”
- “Therapeutic doses of sobetirome did not elicit signs of thyrotoxicity... Notably, there were no effects on heart, markers of bone catabolism or muscle strength.”
- “Sobetirome also safely reduces body fat via induction of thermogenesis. These effects are accompanied by reduced blood glucose in mouse models of Type 2 diabetes and liver fat clearance.”
- “There is no evidence that short uses of sobetirome lead to harmful side effects and this could be useful for controlled, short-term weight loss interventions.”
View attachment 351059
Amino Asylum has it in stock with Jano tests, so does Kimera. Seems they both just got them in within the last weeks.
Will probably order some, seems like a reasonable dosage is
![]()
GC-1 (SOBETIROME) - Soma Chems
GC-1, or Sobetirome, is a selective thyroid hormone receptor β (TRβ) agonist used in research focused on lipid metabolism, cholesterol regulation, andsomachems.com
"Sobetirome is known to cause dose-dependent weight loss in mice (36), and weight loss after 6 to 8 weeks of treatment was observed with the higher 2 mg/kg chow dose of sobetirome (0.4 mg/kg nominal dose) (Fig. 5). Treatment was terminated for the high-dose cohort when weight loss reached 20%, which occurred at 11 weeks for most of these mice. No weight loss was observed at the lower 0.4 mg/kg chow dose of sobetirome (0.08 mg/kg nominal dose), which allowed for 12 weeks of dosing, and a small cohort of animals was treated for an additional 6 weeks (18 weeks total) with no observed weight loss over this period "


